Article
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.
Cells - 16 Nov 2021
Jagomäe Toomas, Seppa Kadri, Reimets Riin, Pastak Marko, Plaas Mihkel, Hickey Miriam A, Kukker Kaia Grete, Moons Lieve, De Groef Lies, Vasar Eero, Kaasik Allen, Terasmaa Anton, Plaas Mario
Abstract excerpt
Wolfram syndrome (WS), also known as a DIDMOAD (diabetes insipidus, early-onset diabetes mellitus, optic nerve atrophy and deafness) is a rare autosomal disorder caused by mutations in the Wolframin1 (WFS1) gene. Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP1 RA) are effective in delaying and restoring blood glucose control in WS animal models and patients. The GLP1 RA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
